A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2015
At a glance
- Drugs IMF 001 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2013 Planned end date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 27 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.